Global Study Looking at the Combination of RAD001 and Sorafenib to Treat Patients With Advanced Hepatocellular Carcinoma
Status:
Terminated
Trial end date:
2011-06-01
Target enrollment:
Participant gender:
Summary
Phase 1 Evaluate the safety and tolerability of RAD001 in combination with sorafenib in
patients with advance hepatocellular cancer (HCC) and to determine the maximum tolerated dose
(MTD)
Phase 2 To estimate the treatment effect as a measure of anti-tumor activity in terms of Time
to Progression (TTP) of the combination of RAD001 plus sorafenib, at the MTD, as compared to
sorafenib alone